BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system

Molecular Cancer Therapeutics

Volumn 15, Issue 6, 2016, Pages 1397-1404

  Janku, Filip ^a   Huang, Helen J ^a   Claes, Bart ^b   Falchook, Gerald S ^a,c   Fu, Siqing ^a   Hong, David ^a   Ramzanali, Nishma M ^a   Nitti, Giovanni ^a   Cabrilo, Goran ^a   Tsimberidou, Apostolia M ^a   Naing, Aung ^a,c   Piha Paul, Sarina A ^a   Wheler, Jennifer J ^a   Karp, Daniel D ^a   Holley, Veronica R ^a   Zinner, Ralph G ^a   Subbiah, Vivek ^a   Luthra, Rajyalakshmi ^a   Kopetz, Scott ^a   Overman, Michael J ^a   Kee, Bryan K ^a   Patel, Sapna ^a   Devogelaere, Benoit ^b,d   Sablon, Erwin ^b   Maertens, Geert ^b   Mills, Gordon B ^a   Kurzrock, Razelle ^a,e   Meric Bernstam, Funda ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Biocartis SA   (Belgium)

^c HealthOne   (United States)

^d Cartagenia   (Belgium)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CELL FREE DNA; DNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOMATED MOLECULAR DIAGNOSTIC SYSTEM; CANCER PATIENT; CANCER SURVIVAL; CELL FREE SYSTEM; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT HISTIOCYTOSIS; MELANOMA; MOLECULAR DIAGNOSTICS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THYROID CANCER; TIME TO TREATMENT; TURNAROUND TIME; BLOOD; DNA MUTATIONAL ANALYSIS; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL-FREE SYSTEM; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84971516426     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0712     Document Type: Article

References (27)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov 2015; 5:64-71.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
4. Robinson SD, O'Shaughnessy JA, Cowey CL, Konduri K. BRAF V600Emutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 2014;85:326-30.
5. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
6. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18: 6373-83.
7. Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, et al. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget 2014;5:3607-10.
8. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
9. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Perez-Fidalgo JA, Wang Y, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 2014;13:1382-9.
10. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14: 985-90.
11. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
12. Diaz LAJr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
13. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
14. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
15. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4: 136ra68.
16. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, et al. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 2015;6:26886-94.
17. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692-6.
18. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
19. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 2015;6: 24581.
20. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462-9.
21. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat 2010;120:461-7.
22. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20:430-5.
23. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012;18:1177-85.
24. Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer 2013;79:312-7.
25. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
26. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
27. Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res 2016;22:567-74.